News articles about Corbus Pharmaceuticals (NASDAQ:CRBP) have been trending somewhat positive this week, Accern reports. Accern ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Corbus Pharmaceuticals earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 44.1758026027413 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the media stories that may have impacted Accern Sentiment’s rankings:

Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) opened at $6.95 on Wednesday. The stock has a market capitalization of $386.44, a P/E ratio of -11.21 and a beta of 151.35. Corbus Pharmaceuticals has a 1 year low of $5.30 and a 1 year high of $10.50.

Corbus Pharmaceuticals (NASDAQ:CRBP) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. The business had revenue of $0.80 million for the quarter. Corbus Pharmaceuticals had a negative return on equity of 96.02% and a negative net margin of 1,040.41%. equities analysts forecast that Corbus Pharmaceuticals will post -0.6 EPS for the current fiscal year.

CRBP has been the topic of several recent analyst reports. Noble Financial lifted their price target on Corbus Pharmaceuticals from $16.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, November 8th. Raymond James Financial initiated coverage on Corbus Pharmaceuticals in a research report on Friday, January 19th. They issued an “outperform” rating and a $24.00 price target on the stock. BidaskClub downgraded Corbus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, Cantor Fitzgerald set a $28.00 price objective on Corbus Pharmaceuticals and gave the company an “overweight” rating in a research report on Thursday, December 14th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $24.75.

In other news, Director David P. Hochman acquired 10,000 shares of the stock in a transaction dated Friday, November 10th. The shares were acquired at an average cost of $7.08 per share, for a total transaction of $70,800.00. Following the completion of the transaction, the director now owns 459,500 shares in the company, valued at approximately $3,253,260. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David P. Hochman acquired 5,000 shares of the stock in a transaction dated Wednesday, November 15th. The shares were purchased at an average price of $6.55 per share, for a total transaction of $32,750.00. Following the completion of the transaction, the director now owns 459,500 shares of the company’s stock, valued at approximately $3,009,725. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 25,336 shares of company stock worth $175,632. 11.90% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION WARNING: “Corbus Pharmaceuticals (CRBP) Earning Somewhat Positive Press Coverage, Study Shows” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The original version of this piece of content can be accessed at

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Insider Buying and Selling by Quarter for Corbus Pharmaceuticals (NASDAQ:CRBP)

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with's FREE daily email newsletter.